Full Papers
Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study
J. Amann1, A.-M. Wessels2, F. Breitenfeldt3, D. Huscher4, J.W. Bijlsma5, J.W. Jacobs6, F. Buttgereit7
- Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany.
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands.
- Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany.
- German Rheumatism Research Center Berlin, Epidemiology, Berlin, Germany.
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands.
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, the Netherlands. j.w.g.jacobs@umcutrecht.nl
- Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany.
CER9729
2017 Vol.35, N°3
PI 0471, PF 0476
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 28094753 [PubMed]
Received: 05/07/2016
Accepted : 10/11/2016
In Press: 15/01/2017
Published: 07/06/2017
Abstract
OBJECTIVES:
EULAR guidelines state that adverse effects (AEs) of glucocorticoid (GC) therapy should be considered and discussed with the patient before treatment is initiated. However, reliable quantitative data, especially on cutaneous AEs of low-to-medium dose GCs are lacking. We performed a study assessing the occurrence of cutaneous AEs of GCs and its association with current and cumulative GC doses in patients with rheumatoid arthritis (RA).
METHODS:
In a cross-sectional study performed in 2 outpatient rheumatology centres, 381 RA patients were enrolled. They were classed into 4 groups, according their mean daily dose during the past 12 months: 0 mg (n=87), <5mg (n=108), 5-7.5 mg (n=130), and >7.5 mg (n=56) of prednisone equivalent. AEs of GC on the skin were assessed by physical examination using a predefined scoring system, and by patients’ self-assessments. Data were analysed according GC dose categories and cumulative doses.
RESULTS:
Cushingoid habitus, easy bruising, skin atrophy, and impaired wound healing as reported by patients occurred significantly more frequently in those using a GC the past 12 months, compared to those not using a GC. At physicians’ assessments, only Cushingoid habitus and ecchymosis were more prevalent in GC users. The prevalence of these AEs was statistically significantly positively associated with current and cumulative GC dose. There was low occurrence of abnormal stretch marks, acne, perioral dermatitis, alopecia and hirsutism, which were not correlated with GC use.
CONCLUSIONS:
Certain GC-associated cutaneous AEs are common in RA, but other AEs of GC occur infrequently at the low-to-medium GC doses used in RA.
